Navigation Links
Regado Biosciences, Inc. Introduces REG2, Its Second Product Candidate, at the American College of Cardiology Conference, 59th Annual Scientific Session, in Atlanta, Georgia on March 15, 2010
Date:3/15/2010

, initially in Acute Coronary Syndrome patients undergoing Percutaneous Coronary Intervention.  REG2, Regado's second product candidate, consists of a subcutaneously administered depot formulation of RB006 paired with the IV bolus formulation of RB007.  REG2 recently completed single escalating dose phase 1 clinical testing and is planned to be studied in a multiple escalating dose clinical trial later in 2010.  It is intended for use in venous thrombosis indications such as venous thromboembolism (VTE) prophylaxis in patients undergoing abdominal surgery.  Information pertaining to Regado's clinical programs may be obtained at www.clinicaltrials.gov.

ABOUT APTAMERS

RB006 is a member of a class of compounds called aptamers.  Aptamers are single stranded oligonucleotides that adopt a specific conformation enabling direct, specific inhibition of the targeted protein.  A key unique feature of aptamers derives from the fact that they are formed from nucleic acids.  As such, their pharmacologic activity can be controlled by a matched, complementary oligonucleotide active control agent (the Watson-Crick base pair complement of a fraction of the agent to be controlled), which can bind to the aptamer, removing it from its target and reversing it biologic effects.


'/>"/>
SOURCE Regado Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Regado Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference on December 1, 2009
2. Regado Biosciences to Present at the Ninth Annual Joint Symposium of BioNJ and Pennsylvania Bio on November 17, 2009
3. Regado Biosciences Releases Positive Phase 2a Data for the Reversible Anticoagulant System REG1 at the European Society of Cardiology Congress In Barcelona, Spain
4. Regado Biosciences Completes Patient Enrollment for Phase IIa Study of REG1 Anticoagulation System
5. Regado Biosciences Reports Clinical Results for REG1 Anticoagulation System at European Society of Cardiology Congress 2008
6. Regado Biosciences Announces Publication in Circulation of Clinical Trial Results of REG1 Anticoagulation System
7. Regado Biosciences Presents Early Stage Clinical Data for REG1 Anticoagulation System at American Heart Association 2007 Scientific Sessions
8. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
9. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
10. Neurocrine Biosciences, Inc. Prices Common Stock Offering
11. Hollis-Eden Announces Name Change to Harbor BioSciences, Inc. and Ticker Symbol Change to HRBR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... EASTON, Mass. , Sept. 19, 2014 /PRNewswire/ ... "Company") today announced it has received and approved ... Barozyme HT48 instruments and has begun to manufacture ... the first instrument will be ready for shipment ... be built and released at a rate of ...
(Date:9/19/2014)... , Sept. 19, 2014  BioSpecifics Technologies Corp. (NASDAQ: ... collagenase-based products marketed as XIAFLEX ® in the U.S. ... BioSpecifics, President, Tom Wegman , will present a corporate ... the Biotech Industry Conference. The presentation will ... EDT at the Millennium Broadway Hotel in New ...
(Date:9/19/2014)... -- Aufgrund der enormen Nachfrage seines ... aktualisiert, der jetzt auch die Jahre 2014 - ... pharmaserialisation.com , zeigt die Serialisierungsanforderungen weltweit und den ... Für international tätige Unternehmen geht es ... sondern darum, "wann" sie die neu in Kraft ...
Breaking Medicine Technology:Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 2Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 3BioSpecifics Technologies Corp. to Present at the 21st Annual BioCentury NewsMakers in the Biotech Industry Conference 2Pharma IQ stellt weltweite Serialisierungsfristen in seinen Countdown-Kalender 2014 - 2018 2
(Date:9/19/2014)... Recent two-generation approaches to reducing poverty that help ... from researchers, advocates, and foundations. By combining education ... move to jobs that offer a path out ... for children, these programs aim to improve the ... a new report from the National Center for ...
(Date:9/19/2014)... at Jacksonville,s campus of Mayo Clinic have discovered a ... to both overproduction of toxic protein in the brains ... loss of communication between neurons both significant contributors ... the online issue of Neuron , ... drugs "may rejuvenate or rescue this pathway," says the ...
(Date:9/19/2014)... (PRWEB) September 19, 2014 Famous Vancouver ... announced that it has now become a one-stop-solution for ... and businesses in Vancouver. The company has achieved this ... services to its customers. While there are many companies ... to have a single vendor who can offer all ...
(Date:9/19/2014)... (PRWEB) September 20, 2014 As summer vacations ... DMD in Queens, NY now reminds area patients about the ... 80% of our population affected by gum disease, there is ... , For over 20 years Dr. Krishnan has treated patients ... office location. “Most patients that come in due to common ...
(Date:9/19/2014)... Sept. 19, 2014 (HealthDay News) -- When it comes ... in the United States, while the District of Columbia ... the past decade, deaths from gun-related violence -- including ... the United States, the study revealed. Hawaii,s rate was ... of the spectrum, the District of Columbia had the ...
Breaking Medicine News(10 mins):Health News:A two generation lens: Current state policies fail to support families with young children 2Health News:Mayo researchers reveal pathway that contributes to Alzheimer's disease 2Health News:Pro Ace Now Provides Heating, Air Conditioning, Plumbing & Electrical Services under One Roof 2Health News:New York Periodontist Dr. Prabha Krishnan Now Raises Awareness about the Dangers of Untreated Decay, Gingivitis and Gum Disease During Self-Awareness Month 2Health News:New York Periodontist Dr. Prabha Krishnan Now Raises Awareness about the Dangers of Untreated Decay, Gingivitis and Gum Disease During Self-Awareness Month 3Health News:U.S. Gun Deaths Lowest in Hawaii, Highest in D.C. 2
... CORONA, Calif., Feb. 19 Watson Pharmaceuticals,Inc. (NYSE: ... branded pharmaceuticals,today reported financial results for its fourth quarter ... Fourth Quarter 2008 Results , ... increased $17.9 million or 3,percent from the fourth quarter ...
... to Vote Gold Card and Reject Dissidents, Director Slate ... (Nasdaq: LCAV ) today announced that it ... it urges support for Company management and its Board ... letter follows: To My Fellow Stockholders:Your LCA-Vision executive Team ...
... Full-Year 2009 OutlookVIRGINIA BEACH, Va., Feb. 19, 2009 AMERIGROUP ... net income for the fourth quarter of 2008 increased 20.0% ... income of $31.1 million, or $0.57 per diluted share, for ... December 31, 2008, the Company,s net loss was $50.7 million, ...
... foundation, announces its series of dental related health care reports under ... ... Springs, CO (PRWEB) February 19, 2009 -- Toxic Elements Research Foundation ... related health care reports under the title of ,Elements of Disease., ...
... greenhouse gas emissions, Oregon will face some $3.3 billion ... tab of about 4 percent of annual household income ... University of Oregon,s Climate Leadership Initiative,s Program on Climate ... Economics is guided by a steering committee of 19 ...
... Sessions begin Saturday, March 14 at 10 a.m. SAN FRANCISCO, ... and Wellness Center , is excited to bring back its ... San Francisco. Starting Saturday, March 14 at 10 a.m., ... Park or in the Presidio (near the Lyon Street Stairs) ...
Cached Medicine News:Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 2Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 3Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 4Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 5Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 6Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 7Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 8Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 9Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 10Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 11Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 12Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 13Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 14Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 15Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 16Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 17Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 18Health News:LCA-Vision Reports Tangible Results from Business Strategy 2Health News:LCA-Vision Reports Tangible Results from Business Strategy 3Health News:LCA-Vision Reports Tangible Results from Business Strategy 4Health News:LCA-Vision Reports Tangible Results from Business Strategy 5Health News:AMERIGROUP Reports Q4 Net Income of $37.3 Million or $0.70 Per Diluted Share 2Health News:AMERIGROUP Reports Q4 Net Income of $37.3 Million or $0.70 Per Diluted Share 3Health News:AMERIGROUP Reports Q4 Net Income of $37.3 Million or $0.70 Per Diluted Share 4Health News:AMERIGROUP Reports Q4 Net Income of $37.3 Million or $0.70 Per Diluted Share 5Health News:AMERIGROUP Reports Q4 Net Income of $37.3 Million or $0.70 Per Diluted Share 6Health News:AMERIGROUP Reports Q4 Net Income of $37.3 Million or $0.70 Per Diluted Share 7Health News:AMERIGROUP Reports Q4 Net Income of $37.3 Million or $0.70 Per Diluted Share 8Health News:AMERIGROUP Reports Q4 Net Income of $37.3 Million or $0.70 Per Diluted Share 9Health News:AMERIGROUP Reports Q4 Net Income of $37.3 Million or $0.70 Per Diluted Share 10Health News:AMERIGROUP Reports Q4 Net Income of $37.3 Million or $0.70 Per Diluted Share 11Health News:AMERIGROUP Reports Q4 Net Income of $37.3 Million or $0.70 Per Diluted Share 12Health News:AMERIGROUP Reports Q4 Net Income of $37.3 Million or $0.70 Per Diluted Share 13Health News:AMERIGROUP Reports Q4 Net Income of $37.3 Million or $0.70 Per Diluted Share 14Health News:AMERIGROUP Reports Q4 Net Income of $37.3 Million or $0.70 Per Diluted Share 15
MONOJECT Red/Yellow Mottled Stopper...
... BD Vacutainer® SST™ Tubes ... a polymer gel for ... used for serum determinations ... provide an efficient means ...
BD Vacutainer® Specialty Tubes - Sedimentation Rate Determination (SRD)...
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
Medicine Products: